Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

4articles mentioning drugs

19drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: ivonescimab ×

ivonescimab

This drug is selected. Its supporting articles are shown below.

Ivonescimab4

Articles mentioning ivonescimab

4 articles · page 1 of 1

440 The combined action of anti-PD-1/VEGF bispecific antibody for inhibition recurrent H3K27M+ diffuse midline gliomas: a pilot case report of Ivonescimab in a DMG patient

jitc · abstract · 2025-11-04 · 8 matching annotations

98.2%

Ivonescimab temozolomide

…ery, lesion recurred; C. Ivonescimab treatment for 3 cycles; D. Ivonescimab treatment for 5 cycles…

1348 Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR+ NSCLC progressed on EGFR-TKI treatment

jitc · abstract · 2025-11-07 · 6 matching annotations

98.7%

Ivonescimab carboplatin pemetrexed EGFR + NSCLC EGFR+ NSCLC ClinicalTrial.gov chemotherapy

…ed favorable, with no new safety signals identified.Conclusions Ivonescimab plus chemotherapy demonstrated a clinically meaningful and stat…

1185 Preclinical development of CR-001, a novel tetravalent PD-1 x VEGF bispecific antibody with cooperative pharmacology and potent anti-tumor activity

jitc · abstract · 2025-11-04 · 3 matching annotations

97.5%

ivonescimab CR-001

… activation in vitro, consistent with preclinical evaluation of ivonescimab. 1 In xenograft models, CR-001 demonstrated potent anti-tumor a…

Neoadjuvant stereotactic body radiotherapy combined with chemotherapy and Ivonescimab for Chinese luminal-type breast cancer patients: study protocol for a single-arm, open-label, phase II trial

bmjopen · abstract · 2025-09-10 · 2 matching annotations

97.9%

Ivonescimab luminal-type breast cancer Hubei Cancer Hospital NCT06402435 chemotherapy Immunotherapy neoadjuvant SBRT stereotactic body radiotherapy

…luate the efficacy and safety of neoadjuvant SBRT combined with Ivonescimab and chemotherapy. A total of 50 patients will be enrolled. The …